Cybin Inc.

Helus Pharma is a clinical-stage pharmaceutical company dedicated to advancing mental health treatments through the development of proprietary novel serotonergic agonists (NSAs). The company's mission is to help minds heal by creating synthetic molecules designed to activate serotonin pathways, which are believed to promote neuroplasticity. Founded in 2019, Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland, with its headquarters located in Toronto, Canada.

The company's pipeline primarily focuses on addressing significant unmet needs in depression, anxiety, and other mental health conditions. Its lead drug candidates include HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, Helus Pharma is developing HLP004, another proprietary NSA, currently in Phase 2 for generalized anxiety disorder. The company leverages proprietary drug delivery systems and patent-protected molecules, holding over 350 patent applications and more than 100 granted patents.

In recent corporate developments, Michael Cola stepped down as Chief Executive Officer on April 20, 2026, with co-founder Eric So resuming the role of Interim CEO. Helus Pharma recently partnered with TARA Mind to support recruitment for its HLP003 Phase 3 clinical trial, particularly within the veteran community, aligning with a White House Executive Order aimed at accelerating mental health treatments. The company, formerly known as Cybin Inc., rebranded to Helus Pharma in December 2025 and transferred its U.S. stock listing to Nasdaq in January 2026, reflecting its evolution towards a commercial-ready pharmaceutical entity focused on late-stage clinical development.